PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
18 hedge funds and large institutions have $10.8M invested in PLx Pharma Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
29% more funds holding
Funds holding: 14 → 18 (+4)
3% more capital invested
Capital invested by funds: $10.5M → $10.8M (+$309K)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$1.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$228K |
| 3 |
Renaissance Technologies
New York
|
+$144K |
| 4 |
Fayez Sarofim & Co
Houston,
Texas
|
+$88.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$75.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$500K |
| 2 |
6CM
683 Capital Management
New York
|
-$267K |
| 3 |
Goldman Sachs
New York
|
-$70K |
| 4 |
HWA
Heritage Way Advisors
Rockford,
Illinois
|
-$26.3K |
| 5 |
BlackRock
New York
|
-$706 |
PLXP Hedge Fund Activity: Q3 2017 in Review
18 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2017, worth a combined $10.8M — up 2.9% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PLXP positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Harel Insurance Investments & Financial Services, opening a new position worth an estimated $1.6M. The largest seller was Susquehanna International Group, cutting an estimated $500K.
- 18 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2017, up from 14 in Q2 2017.
- Funds reported $10.8M of PLx Pharma Inc. Common Stock stock for Q3 2017, up 2.9% quarter-over-quarter.
- 7 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2017 and 2 closed out, a net change of +5 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q3 2017 was Harel Insurance Investments & Financial Services, an estimated $1.6M added.
- The largest PLx Pharma Inc. Common Stock seller in Q3 2017 was Susquehanna International Group, an estimated $500K sold.
Based on aggregated 13F filings for Q3 2017.